BiotechTube

AZD4076 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T2DM With NAFLD

Conditions

T2DM With NAFLD

Trial Timeline

Jul 18, 2016 → Oct 11, 2019

NCT ID
NCT02826525

About AZD4076 + Placebo

AZD4076 + Placebo is a phase 1 stage product being developed by AstraZeneca for T2DM With NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT02826525. Target conditions include T2DM With NAFLD.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT02826525Phase 1Completed
NCT02612662Phase 1Completed

Competing Products

20 competing products in T2DM With NAFLD

See all competitors
ProductCompanyStageHype Score
MKP10241 + PlaceboMankind PharmaPhase 2
52
Metformin + Alogliptin + empagliflozinCelltrionPhase 3
77
CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + MetforminCelltrionPhase 3
77
L03RD1 + L03RD2 + CT-L03CelltrionPhase 1
33
DulaglutideEli LillyPhase 1
33
SHR-3167 + SHR-3167 PlaceboJiangsu Hengrui MedicinePhase 1
33
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
85
Dapagliflozin + Metformin XR + GlucophageAstraZenecaPhase 1
33
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+PlaceboAstraZenecaPhase 1
33
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mgAstraZenecaPhase 1
33
Comparator: sitagliptin phosphate + Comparator: placebo (unspecified)MerckPhase 1
33
ErtugliflozinMerckPhase 1
33
Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptinMerckPhase 1
33
Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
85
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
77
Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
85
LIK066 + PlaceboNovartisPhase 1/2
41
Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3
77
Maridebart cafraglutide + PlaceboAmgenPhase 3
76
Maridebart Cafraglutide + PlaceboAmgenPhase 2
51

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85